Literature DB >> 17401753

[Assessment of the natural history of coronary artery calcification and identification of its determinants. Rationale of the 2nd part of the Heinz Nixdorf Recall Study].

Stefan Möhlenkamp1, Susanne Moebus, Axel Schmermund, Nils Lehmann, Barbara Hoffmann, Till Neumann, Andreas Stang, Nico Dragano, Gert Kerkhoff, Christoph Naber, Hagen Kälsch, Eva-Maria Beck, Martina Bröcker-Preuss, Knut Kröger, Thomas Budde, Johannes Siegrist, Klaus Mann, Karl-Heinz Jöckel, Raimund Erbel.   

Abstract

The Heinz Nixdorf Recall Study, which was inaugurated in 2000, is an ongoing population-based study to evaluate the prediction of cardiovascular events by integrating new imaging and nonimaging modalities in risk assessment. A focus is the additional prognostic value of coronary artery calcification (CAC). Currently used risk stratification algorithms often describe the individuals' risk based on few established risk factors only inaccurately. Using noninvasive quantification of CAC progression, the natural history of atherosclerosis with its repetitive, frequently subclinical plaque ruptures, may detect an unstable course of the disease long before the disease irreversibly manifests in sudden death or myocardial infarction. While the independent additional prognostic value of CAC quantification has been shown in asymptomatic patients at intermediate risk, only few studies provided evidence for an independent prognostic value of serial CAC measurements. In the Heinz Nixdorf Recall Study, the impact of established and new risk factors, e.g., the metabolic syndrome, psychosocial and environmental risk factors, or genetic variables, can be assessed. Further, the association of CAC progression with the incidence of other cardiovascular diseases such as heart failure or aortic or aortic valve calcification can be described. Since April 2006, the participants of the study return to the study center 5 years after baseline recruitment to assess health status and to determine the risk factor profile. Based on recently published data, serial CAC measurements have been granted allowing for (1) characterization of the natural history of CAC progression, and (2) identification of its determinants. The rationale of serial CAC quantification is discussed in this article.The Heinz Nixdorf Recall Study will contribute to the appraisal of new imaging modalities in risk stratification.

Entities:  

Mesh:

Year:  2007        PMID: 17401753     DOI: 10.1007/s00059-007-2982-3

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  4 in total

1.  Comparison of dual-source and electron-beam CT for the assessment of coronary artery calcium scoring.

Authors:  N Reinsch; A A Mahabadi; N Lehmann; S Möhlenkamp; C Hoefs; B Sievers; T Budde; R Seibel; K-H Jöckel; R Erbel
Journal:  Br J Radiol       Date:  2011-10-18       Impact factor: 3.039

2.  Prevalence of thoracic aortic calcification and its relationship to cardiovascular risk factors and coronary calcification in an unselected population-based cohort: the Heinz Nixdorf Recall Study.

Authors:  Hagen Kälsch; Nils Lehmann; Stefan Möhlenkamp; Cornelia Hammer; Amir A Mahabadi; Susanne Moebus; Axel Schmermund; Andreas Stang; Marcus Bauer; Karl-Heinz Jöckel; Raimund Erbel
Journal:  Int J Cardiovasc Imaging       Date:  2012-04-22       Impact factor: 2.357

3.  Association of coronary artery calcium and congestive heart failure in the general population: Results of the Heinz Nixdorf Recall study.

Authors:  H Kälsch; N Lehmann; S Möhlenkamp; T Neumann; U Slomiany; Axel Schmermund; Andreas Stang; S Moebus; M Bauer; K Mann; K-H Jöckel; R Erbel
Journal:  Clin Res Cardiol       Date:  2010-03       Impact factor: 5.460

4.  [Distribution of carotid intima media thickness in men and women with and without coronary heart disease. Cross-sectional data of the Heinz Nixdorf Recall Study].

Authors:  M Bauer; B Hoffmann; S Möhlenkamp; N Lehmann; S Moebus; U Roggenbuck; C Berg; H Kälsch; A A Mahabadi; K Kara; K-H Jöckel; R Erbel
Journal:  Herz       Date:  2012-11-25       Impact factor: 1.443

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.